RCS - Destiny Pharma PLC - Presenting at HC Wainwright Investment Conference

Destiny PharmaAnnouncement

07/09/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220907:nRSG5119Ya&default-theme=true

RNS Number : 5119Y  Destiny Pharma PLC  07 September 2022

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Destiny Pharma CEO, Neil Clark, to present

at the HC Wainwright 24(th) Annual Global Investment Conference

 

Brighton, United Kingdom - 7 September 2022 - Destiny Pharma plc (AIM:DEST),
 a clinical stage biotechnology company focused on the development of novel
products to prevent life-threatening infections, today announces that Destiny
Pharma's CEO, Neil Clark, will present virtually at the upcoming HC Wainwright
24 (https://hcwevents.com/annualconference/) (th
(https://hcwevents.com/annualconference/) ) Annual Global Investment
Conference (https://hcwevents.com/annualconference/) , being held on 12-14
September 2022 in New York and virtually.

The presentation will be available to view on demand from 1200 BST / 0700 ET
on Monday 12 September 2022.  To join the conference virtually, view the
presentation and ask any questions, please click on the link above to
register.

Presentation Title:     Destiny Pharma Company Presentation

Presenter:                   Neil Clark

If you would like to meet with Destiny Pharma, please email us at
conferences@destinypharma.com (mailto:conferences@destinypharma.com) or
contact us through the HC Wainwright conference meeting system
(https://hcwevents.com/annualconference/) if you are registered.

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440
pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

Optimum Strategic Communications
Mary Clark / Manel Mateus

+44 (0) 208 078 4357
DestinyPharma@optimumcomms.com (mailto:DestinyPharma@optimumcomms.com)

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

Stern IR - US

Lilian Stern / Janhavi Mohite

+1-212-362-1200

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2b clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SporCov, a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF research projects.

For further information on the company, please visit
https://www.destinypharma.com (https://www.destinypharma.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAMZGGLRVVGZZM